Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia
Metrics: PDF 602 views | HTML 765 views | ?
Fabio Giuseppe Liberante1, Tara Pouryahya1, Mary-Frances McMullin1, Shu-Dong Zhang1,*, Kenneth Ian Mills1,*
1Centre for Cancer Research and Cell Biology (CCRCB), Queen's University Belfast, Belfast, United Kingdom
*These authors contributed equally to this work
Fabio Giuseppe Liberante, e-mail: email@example.com
Keywords: myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), bromocriptine, re-purposed, therapy
Received: July 03, 2015 Accepted: November 28, 2015 Published: December 28, 2015
Myelodysplastic syndromes (MDS) represent a broad spectrum of diseases characterized by their clinical manifestation as one or more cytopenias, or a reduction in circulating blood cells. MDS is predominantly a disease of the elderly, with a median age in the UK of around 75. Approximately one third of MDS patients will develop secondary acute myeloid leukemia (sAML) that has a very poor prognosis. Unfortunately, most standard cytotoxic agents are often too toxic for older patients. This means there is a pressing unmet need for novel therapies that have fewer side effects to assist this vulnerable group. This challenge was tackled using bioinformatic analysis of available transcriptomic data to establish a gene-based signature of the development and progression of MDS. This signature was then used to identify novel therapeutic compounds via statistically-significant connectivity mapping. This approach suggested re-purposing an existing and widely-prescribed drug, bromocriptine as a novel potential therapy in these disease settings. This drug has shown selectivity for leukemic cells as well as synergy with current therapies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.